September 18, 2025

'Integrity Cannot Be Replaced': Ousted CDC Leader Speaks Out

Testimony from former CDC leadership highlighted differences with federal health officials on the process for reviewing and implementing vaccine policies.

KFF Health News

September 17, 2025

‘Death by a Thousand Cuts’

Rural South Texas hospitals and physicians face mounting strain as rising uninsured rates and federal funding cuts threaten access to essential health care.

KFF Health News

September 16, 2025

RFK Jr. Panel Weighs Hepatitis B Delay

Advisory committee members may push to move the hepatitis B vaccine to age 4, despite warnings from clinicians.

KFF Health News

September 12, 2025

FDA Considers Ending Routine Advisory Committees on New Drugs

The FDA move to limit advisory committee involvement in drug approvals has prompted debate on the balance between efficiency and transparency.

KFF Health News

September 10, 2025

Medical Societies Challenge Kennedy

"That you can no longer trust the recommendations out of the CDC is just devastating."

Conexiant

September 08, 2025

FDA Expands Indications for Von Willebrand Disease

FDA expands Vonvendi to adult routine prophylaxis (types 1 and 2) and pediatric on-demand/perioperative use.

Conexiant

September 03, 2025

CDC Leadership Changes May Impact Vaccine Guidance

Leadership changes at the CDC could affect vaccine guidance and public health policy, with potential implications for physicians and patient care.

KFF Health News

September 03, 2025

Policy Shift Adjusts NIH Peer Review Role

New NIH funding rules shift decision-making power from peer review panels to political appointees in determining future scientific grants.

KFF Health News

September 02, 2025

New Bruton’s Tyrosine Kinase Inhibitor Improves Platelet Response

The FDA has approved rilzabrutinib (Wayrilz) as the first Bruton’s tyrosine kinase inhibitor for adults with chronic or persistent immune thrombocytopenia who have had an insufficient response to prior therapy.

Conexiant